tirzepatide cvot SURPASS-CVOT trial: For patients with high-risk type 2 diabetes, the effect of tirzepatide, a dual agonist of the GLP-1 and glucose-dependent insulinotropic polypeptide receptors, on cardiovascular outcomes is uncertain. Research is summarized SURPASS-CVOT: Tirzepatide better than dulagluti...

Keep in mind there is no conclusive evidence that LIPO-C is proven for weight loss

The presence of these antibodies has the potential to increase the risk of local skin reactions, hypersensitivity, or anaphylactic reactions and may also neutralize the therapeutic effects of GLP-1 receptor agonists

These underlying issues must be addressed to achieve long-term freedom from obsessive food thoughts. Food thoughts may return when your body gets used to the dose Some who stop binge eating with Ozempic find that their food cravings return once their body adjusts to the dose

While Ozempic can curb food noise in the short term, there is no long-term data